

## PATIENT INFORMATION

GAVRETO® (gav-REH-toh)  
(pralsetinib)  
capsules

### What is GAVRETO?

GAVRETO is a prescription medicine used to treat certain cancers caused by abnormal rearranged during transfection (RET) genes in:

- adults with non-small cell lung cancer (NSCLC) that has spread.
- adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread who require a medicine by mouth or injection (systemic therapy) and who have received radioactive iodine and it did not work or is no longer working.

Your healthcare provider will perform a test to make sure that GAVRETO is right for you.

It is not known if GAVRETO is safe and effective when used to treat cancers caused by abnormal RET genes:

- in children for the treatment of NSCLC **or**
- in children younger than 12 years of age for the treatment of thyroid cancer.

### Before taking GAVRETO, tell your healthcare provider about all of your medical conditions, including if you:

- have lung or breathing problems other than lung cancer
- have high blood pressure
- have bleeding problems
- have liver problems
- plan to have surgery. You should stop taking GAVRETO at least 5 days before your planned surgery. See “**What are the possible side effects of GAVRETO?**”
- are pregnant or plan to become pregnant. GAVRETO can harm your unborn baby.

#### **Females who are able to become pregnant:**

- Your healthcare provider will do a pregnancy test before you start treatment with GAVRETO.
- You should use an effective form of non-hormonal birth control (contraception) during treatment and for **2 weeks** after your last dose of GAVRETO.
- Birth control methods that contain hormones (such as birth control pills, injections or transdermal system patches) may not work as well during treatment with GAVRETO.
- Talk to your healthcare provider about birth control methods that may be right for you during this time.
- Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with GAVRETO.

#### **Males with female partners who are able to become pregnant:**

- You should use effective birth control (contraception) during treatment and for **1 week** after your last dose of GAVRETO.
- are breastfeeding or plan to breastfeed. It is not known if GAVRETO passes into your breast milk. Do not breastfeed during treatment and for **1 week** after your last dose of GAVRETO.

**Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking GAVRETO with other medicines may affect how GAVRETO works.

### How should I take GAVRETO?

- Take GAVRETO exactly as your healthcare provider tells you to take it.
- Take your prescribed dose of GAVRETO 1 time each day.
- Take GAVRETO on an empty stomach. **Do not** eat for at least 2 hours before and at least 1 hour after taking GAVRETO.
- **Do not** change your dose or stop taking GAVRETO unless your healthcare provider tells you to.
- Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with GAVRETO if you develop side effects.
- If you miss a dose of GAVRETO, take it as soon as possible on the same day. Then take your next dose of GAVRETO at your regular time the next day.
- If you vomit after taking a dose of GAVRETO, do not take an extra dose. Take your next dose of GAVRETO at your regular time the next day.

### What are the possible side effects of GAVRETO?

**GAVRETO may cause serious side effects, including:**

- **Lung problems.** GAVRETO may cause severe or life-threatening inflammation of the lungs during treatment, that can lead to death. Tell your healthcare provider right away if you have any new or worsening symptoms, including:
  - shortness of breath
  - cough
  - fever

- **High blood pressure (hypertension).** High blood pressure is common with GAVRETO and may sometimes be severe. You should check your blood pressure regularly during treatment with GAVRETO. Tell your healthcare provider if you have increased blood pressure readings or get any symptoms of high blood pressure, including:
  - confusion
  - dizziness
  - headaches
  - chest pain
  - shortness of breath
- **Liver problems.** Liver problems (increased liver function blood test results) can happen during treatment with GAVRETO and may sometimes be serious. Your healthcare provider will do blood tests before and during treatment with GAVRETO to check you for liver problems. Tell your healthcare provider right away if you get any signs or symptoms of liver problem during treatment, including:
  - yellowing of your skin or the white part of your eyes (jaundice)
  - loss of appetite
  - nausea or vomiting
  - dark “tea-colored” urine
  - pain on the upper right side of your stomach area
  - sleepiness
  - bleeding or bruising
- **Bleeding problems.** GAVRETO can cause bleeding which can be serious and cause death. Tell your healthcare provider if you have any signs or symptoms of bleeding during treatment, including:
  - vomiting blood or if your vomit looks like coffee grounds
  - unusual vaginal bleeding
  - nose bleeds that happen often
  - pink or brown urine
  - drowsiness or difficulty being awakened
  - red or black (looks like tar) stools
  - confusion
  - coughing up blood or blood clots
  - headache
  - unusual bleeding or bruising of your skin
  - change in speech
  - menstrual bleeding that is heavier than normal
- **Tumor lysis syndrome (TLS).** TLS is caused by a fast breakdown of cancer cells. TLS can cause you to have kidney failure and the need for dialysis treatment, an abnormal heartbeat, and may sometimes lead to hospitalization. Your healthcare provider may do blood tests to check you for TLS. You should stay well hydrated during treatment with GAVRETO. Call your healthcare provider or get emergency medical help right away if you develop any of these symptoms during treatment with GAVRETO:
  - nausea
  - shortness of breath
  - vomiting
  - muscle cramps
  - weakness
  - seizures
  - swelling
- **Risk of wound healing problems.** Wounds may not heal properly during treatment with GAVRETO. Tell your healthcare provider if you plan to have any surgery before or during treatment with GAVRETO.
  - You should not take GAVRETO for at least 5 days before surgery.
  - Your healthcare provider should tell you when you may start taking GAVRETO again after surgery.

**The most common side effects of GAVRETO include:**

- muscle and joint pain
- swelling of your face, arms, legs, hands, and feet (edema)
- constipation
- fever
- diarrhea
- cough
- tiredness

**The most common severe abnormal blood test results with GAVRETO include:**

- decreased white blood cell, red blood cell, and platelet counts
- decreased levels of phosphate, body salt (sodium), calcium and potassium in the blood
- abnormal liver function blood tests
- increased levels of enzyme called alkaline phosphatase in the blood (test for liver or bone problems)
- increased levels of potassium in the blood

GAVRETO may affect fertility in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all the possible side effects of GAVRETO.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

**How should I store GAVRETO?**

- Store GAVRETO at room temperature between 68°F to 77°F (20°C to 25°C).
- Protect GAVRETO from moisture.

**Keep GAVRETO and all medicines out of the reach of children.**

**General information about the safe and effective use of GAVRETO.**

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use GAVRETO for a condition for which it was not prescribed. Do not give GAVRETO to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about GAVRETO that is written for health professionals.

**What are the ingredients in GAVRETO?**

**Active ingredient:** pralsetinib

**Inactive ingredients:** citric acid, hydroxypropyl methylcellulose (HPMC), magnesium stearate, microcrystalline cellulose (MCC), pregelatinized starch and sodium bicarbonate.

Capsule shell: FD&C Blue #1 (Brilliant Blue FCF), hypromellose and titanium dioxide.

White printing ink: butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac, strong ammonia solution and titanium dioxide.

Manufactured for: **Genentech, Inc.**, A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990

Jointly marketed by: Genentech USA, Inc. and Blueprint Medicines Corporation

GAVRETO® is a registered trademark of Blueprint Medicines Corporation.

© 2023 Genentech, Inc.

© 2023 Blueprint Medicines Corporation.

For more information, go to [www.GAVRETO.com](http://www.GAVRETO.com) or call 1-888-835-2555.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Revised: 08/2023